Geoffrey Kim

3.4k total citations
29 papers, 1.0k citations indexed

About

Geoffrey Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Geoffrey Kim has authored 29 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Economics and Econometrics. Recurrent topics in Geoffrey Kim's work include Cancer Immunotherapy and Biomarkers (7 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers) and Economic and Financial Impacts of Cancer (4 papers). Geoffrey Kim is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers) and Economic and Financial Impacts of Cancer (4 papers). Geoffrey Kim collaborates with scholars based in United States, China and Switzerland. Geoffrey Kim's co-authors include Richard Pazdur, Shenghui Tang, V. Ellen Maher, Harpreet Singh, Lijun Zhang, Rajeshwari Sridhara, Julia A. Beaver, Kirsten B. Goldberg, Daniel L. Suzman and Sean Khozin and has published in prestigious journals such as Journal of Clinical Oncology, Nature Reviews Drug Discovery and Cancer.

In The Last Decade

Geoffrey Kim

29 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Geoffrey Kim United States 18 621 354 205 156 142 29 1.0k
T. Barnes Canada 12 610 1.0× 256 0.7× 173 0.8× 176 1.1× 157 1.1× 28 988
Martha Donoghue United States 16 696 1.1× 400 1.1× 247 1.2× 157 1.0× 285 2.0× 27 1.2k
Timothée Olivier Switzerland 15 463 0.7× 341 1.0× 123 0.6× 65 0.4× 119 0.8× 83 873
Gunnar Wagenius Sweden 23 873 1.4× 600 1.7× 417 2.0× 130 0.8× 164 1.2× 80 1.5k
Pallavi S. Mishra‐Kalyani United States 22 883 1.4× 560 1.6× 332 1.6× 197 1.3× 191 1.3× 49 1.5k
Gisela Schwab United States 13 644 1.0× 352 1.0× 361 1.8× 166 1.1× 126 0.9× 23 1.3k
Véronique D’Hondt France 21 781 1.3× 335 0.9× 298 1.5× 120 0.8× 241 1.7× 83 1.3k
Chana Weinstock United States 12 558 0.9× 301 0.9× 127 0.6× 106 0.7× 119 0.8× 44 842
Anna Minchom United Kingdom 19 697 1.1× 605 1.7× 343 1.7× 118 0.8× 154 1.1× 110 1.1k
Nitin Roper United States 16 421 0.7× 185 0.5× 461 2.2× 80 0.5× 187 1.3× 44 1.2k

Countries citing papers authored by Geoffrey Kim

Since Specialization
Citations

This map shows the geographic impact of Geoffrey Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geoffrey Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geoffrey Kim more than expected).

Fields of papers citing papers by Geoffrey Kim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geoffrey Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geoffrey Kim. The network helps show where Geoffrey Kim may publish in the future.

Co-authorship network of co-authors of Geoffrey Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Geoffrey Kim. A scholar is included among the top collaborators of Geoffrey Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geoffrey Kim. Geoffrey Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xia, Yujia, Jie Zhou, Luke Johnston, et al.. (2024). Deep learning for oncologic treatment outcomes and endpoints evaluation from CT scans in liver cancer. npj Precision Oncology. 8(1). 263–263. 5 indexed citations
2.
Xia, Yujia, Jie Zhou, Ting Wei, et al.. (2024). CT-based multimodal deep learning for non-invasive overall survival prediction in advanced hepatocellular carcinoma patients treated with immunotherapy. Insights into Imaging. 15(1). 214–214. 6 indexed citations
3.
Gao, Peng, Justin Chen, Chao Liu, et al.. (2023). Landscape of cancer clinical trials in India – a comprehensive analysis of the Clinical Trial Registry-India. The Lancet Regional Health - Southeast Asia. 24. 100323–100323. 3 indexed citations
4.
Wedam, Suparna, Julia A. Beaver, Laleh Amiri‐Kordestani, et al.. (2018). US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments. Journal of Clinical Oncology. 36(12). 1225–1231. 13 indexed citations
5.
Herzog, Thomas J., Gwynn Ison, Ronald D. Alvarez, et al.. (2017). FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper. Gynecologic Oncology. 147(1). 3–10. 29 indexed citations
6.
Walker, Amanda J., Hyun Kim, Haleh Saber, et al.. (2017). Clinical Development of Cancer Drugs in Combination With External Beam Radiation Therapy: US Food and Drug Administration Perspective. International Journal of Radiation Oncology*Biology*Physics. 98(1). 5–7. 6 indexed citations
7.
Weinstock, Chana, Sean Khozin, Daniel L. Suzman, et al.. (2017). U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 23(16). 4534–4539. 115 indexed citations
8.
Khozin, Sean, Geoffrey Kim, & Richard Pazdur. (2017). From big data to smart data: FDA's INFORMED initiative. Nature Reviews Drug Discovery. 16(5). 306–306. 22 indexed citations
9.
Kanapuru, Bindu, Harpreet Singh, Lola A. Fashoyin‐Aje, et al.. (2017). FDA analysis of patient enrollment by region in clinical trials for approved oncological indications.. Journal of Clinical Oncology. 35(15_suppl). 2539–2539. 4 indexed citations
10.
Singh, Harpreet, Bindu Kanapuru, Lola A. Fashoyin‐Aje, et al.. (2017). FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the U.S. Food and Drug Administration.. Journal of Clinical Oncology. 35(15_suppl). 10009–10009. 109 indexed citations
11.
Beaver, Julia A., Abraham Tzou, Gideon M. Blumenthal, et al.. (2016). An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies. Clinical Cancer Research. 23(6). 1368–1372. 26 indexed citations
12.
Khozin, Sean, et al.. (2016). Evaluating the potential for digital submission of expedited premarket safety reports to the FDA. Nature Reviews Drug Discovery. 15(10). 670–671. 3 indexed citations
13.
Singh, Harpreet, Julia A. Beaver, Geoffrey Kim, & Richard Pazdur. (2016). Enrollment of older adults on oncology trials: An FDA perspective. Journal of Geriatric Oncology. 8(3). 149–150. 40 indexed citations
14.
Amiri‐Kordestani, Laleh, Joyce Cheng, Lijun Zhang, et al.. (2016). Association of clinical benefit rate (CBR) with survival: A pooled-analysis of metastatic breast cancer (MBC) trials submitted to the U.S. Food and Drug Administration (FDA).. Journal of Clinical Oncology. 34(15_suppl). e18091–e18091. 5 indexed citations
15.
Sheng, Calvin C., Laleh Amiri‐Kordestani, Todd R. Palmby, et al.. (2016). 21st Century Cardio-Oncology. JACC Basic to Translational Science. 1(5). 386–398. 33 indexed citations
16.
Ricks, Tiffany K., Haw-Jyh Chiu, Gwynn Ison, et al.. (2015). Successes and Challenges of PARP Inhibitors in Cancer Therapy. Frontiers in Oncology. 5. 222–222. 57 indexed citations
17.
Jarow, Jonathan P., V. Ellen Maher, Shenghui Tang, et al.. (2015). Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder Cancer. Bladder Cancer. 1(2). 133–136. 13 indexed citations
18.
Ning, Yang‐Min, Michael H. Brave, V. Ellen Maher, et al.. (2015). U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. The Oncologist. 20(8). 960–966. 35 indexed citations
19.
Yu, Minshu, Amanda J. Walker, Geoffrey Kim, et al.. (2012). L‐asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer. Journal of Cellular and Molecular Medicine. 16(10). 2369–2378. 52 indexed citations
20.
Kim, Geoffrey, Ben Davidson, Junbai Wang, et al.. (2011). Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome. Cancer. 118(6). 1543–1553. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T. Barnes Breakdown of academic impact, for papers by Martha Donoghue Breakdown of academic impact, for papers by Timothée Olivier Breakdown of academic impact, for papers by Gunnar Wagenius Breakdown of academic impact, for papers by Pallavi S. Mishra‐Kalyani Breakdown of academic impact, for papers by Gisela Schwab Breakdown of academic impact, for papers by Véronique D’Hondt Breakdown of academic impact, for papers by Chana Weinstock Breakdown of academic impact, for papers by Anna Minchom Breakdown of academic impact, for papers by Nitin Roper
Rankless by CCL
2026